IMV Inc (NASDAQ:IMV) Stock Falls After The Recent Rally

The clinical stage biopharmaceutical firm IMV Inc (NASDAQ:IMV) had made a strong move not too long ago but on Wednesday the stock suffered from a strong selloff and ended the day with losses of as much as 11.50%.

The company is involved in the development of unique immunotherapies for the purposes of treating the variants of cancer which are difficult to tackle. Earlier on this week on Tuesday, the company was in the news after it announced the final results for the product MVP-S from the DeCidE1 Phase 2 clinical trial. It was a major boost for IMV since the top line results from the trial proved to be highly positive.

In this regard, it should be noted that the results may have been reason behind the rally in the IMV Inc stock not too long ago as well. The Principal Investigator of the DeCidE1 Phase 2 clinical trial, Dr. Oliver Dorigo also spoke about the results. He stated that the results were positive and then went on to add that the product was not only well tolerated but the overall survival rate also touched as much as 44.9%. It  is not going to be interesting to see if the stock can actually make a recovery today and end the week on a stronger footing.